Honda K, et al. - The recently identified unique processing patterns of apolipoprotein A2 (ApoA2) in patients with pancreatic cancer led to this present investigation wherein researchers, for the first time, prospectively assessed if an ApoA2 isoform (“ApoA2-ATQ/AT”), alone and in combination with carbohydrate antigen 19-9 (CA19-9), could be useful as an early detection biomarker for pancreatic cancer. They found that, under usual care, the detection of pancreatic cancer up to 18 months prior to diagnosis could be improved with the combination of CA19-9 and ApoA2-ATQ/AT vs CA19-9 alone. Furthermore, the combination of CA19-9 and ApoA2-ATQ/AT could have utility as a first measure for pancreatic cancer detection prior to imaging.